With bioinformatic and experimental approaches, we have demonstrated that medium‐dose formoterol treatment attenuated EPO‐induced AAA mainly by targeting VSMC senescence via β2AR/cAMP/SIRT1 signals (Figure 9). Here, EPO is linked to triple-A syndrome.